Dabrafenib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dabrafenib and local guidelines before prescribing.
Kinase inhibitor
Mechanism
BRAF kinase inhibitor.
Uses
BRAF V600 melanoma, lung and thyroid cancers (with trametinib).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Pyrexia, rash, cardiomyopathy, new skin cancers, hyperglycaemia.
Interactions
CYP3A4 interactions.
Contraindications and cautions
Pregnancy
Monitoring
LVEF, skin, glucose
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Fever pathway and skin checks.
More from the textbook: uses, cautions and other points
- Adjuvant treatment (stage IIB–III, after surgery) - immunotherapy (pembrolizumab or nivolumab) for 1 year, or BRAF/MEK inhibitors (dabrafenib with trametinib) if BRAF-mutated. Neoadjuvant immunotherapy for some resectable stage III disease.
Oncology: Skin Cancer - Dabrafenib + trametinib | BRAF-mutated melanoma; fever, rash.
Oncology: Skin Cancer - Adjuvant treatment (after surgery for high-risk stage IIB–III) - immunotherapy (pembrolizumab, nivolumab) or BRAF/MEK inhibitors (dabrafenib with trametinib) for BRAF-mutant stage III.
Dermatology: Skin lesions and skin cancer - Dabrafenib + trametinib | BRAF V600-mutant melanoma - fever (pyrexia syndrome).
Dermatology: Skin lesions and skin cancer - BRAF/MEK | Dabrafenib + trametinib | BRAF V600E melanoma
Cell Biology: Cell cycle, signalling, cell death and stem cells
Where it is discussed in the book
- Oncology: Skin Cancer (2 mentions)
- Dermatology: Skin lesions and skin cancer (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)